Table 6.
Association between patient variables and the occurrence of adverse events with anakinra treatment
| Any adverse event | Non cutaneous adverse event | |||||||
|---|---|---|---|---|---|---|---|---|
| Patient variables | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Paediatric vs. adult | 5.67 (2.37 to 13.60) | 0.0001 | 3.27 (1.16 to 9.21) | 0.03 | 1.83 (0.90 to 3.73) | 0.10 | - | n.s. |
| Treatment duration | 2.12 (1.15 to 3.89) | 0.02 | - | n.s | 2.61 (1.34 to 5.13) | 0.005 | 3.37 (1.46 to 7.80) | 0.01 |
| Background treatment: | ||||||||
| Methotrexate | 0.44 (0.21 to 0.95) | 0.03 | - | n.s. | 0.61 (0.26 to 1.41) | 0.25 | - | n.s. |
| All DMARDs | 0.47 (0.23 to 0.98) | 0.04 | 0.27 (0.11 to 0.64) | 0.003 | 0.72 (0.33 to 1.59) | 0.42 | ||
| Corticosteroids | 1.17 (0.57 to 2.38) | 0.68 | 0.82 (0.38 to 1.75) | 0.62 | ||||
| NSAIDs | 1.38 (0.58 to 3.29) | 0.47 | 0.67 (0.26 to 1.74) | 0.41 | ||||
| Disease: | ||||||||
| AOSD | 1.36 (0.72 to 2.57) | 0.35 | - | n.s. | 0.91 (0.46 to 1.79) | 0.78 | ||
| sJIA | 6.53 (1.87 to 22.7) | 0.004 | - | n.s. | 1.42 (0.58 to 3.48) | 0.45 | ||
| Gout | 0.06 (0.02 to 0.21) | 0.0001 | 0.05 (0.001 to 0.24) | 0.0002 | 0.07 (0.01 to 0.51) | 0.01 | - | n.s. |
| CAPS | 1.37 (0.52 to 3.61) | 0.53 | - | n.s. | 1.97 (0.77 to 5.10) | 0.16 | - | n.s. |
OR: odds ratio. 95% CI: 95% confidence interval, DMARDs: disease-modifying anti-rheumatic drugs, NSAIDs : non-steroidal anti-inflammatory drugs, AOSD: adult onset Still’s disease, sJIA: systemic juvenile idiopathic arthritis, CAPS: cryopyrin associated periodic syndrome. n.s.: not significant.